Peyton Huang
About Peyton Huang
Peyton Huang is a Non-Executive Director and Co-Founder of Verge Genomics, where he has worked since 2016. He has a background in medicine and neuroscience, having studied at UCLA and Princeton University, and is actively involved in addressing significant medical challenges such as ALS and Alzheimer's Disease.
Work at Verge Genomics
Peyton Huang serves as the Non-Executive Director and Co-Founder of Verge Genomics, a position he has held since 2016. Based in the San Francisco Bay Area, he has played a pivotal role in the company's mission to address significant medical challenges, including ALS, Parkinson’s Disease, and Alzheimer’s Disease. Under his leadership, Verge Genomics has successfully raised $134 million from prominent investors such as BlackRock, Eli Lilly, and Merck GHI. Huang has also contributed to the development of one of the largest proprietary patient genomics datasets in the field, enhancing the company's research capabilities.
Education and Expertise
Peyton Huang has an extensive educational background in the medical and scientific fields. He studied at Princeton University, where he earned an A.B. in Molecular Biology with high honors. Following this, he pursued an MD/PhD at the David Geffen School of Medicine at UCLA, completing his studies from 2011 to 2015. His academic training has equipped him with a deep understanding of neuroscience and genomics, which he applies in his current roles.
Background
Before co-founding Verge Genomics, Peyton Huang was an MD/PhD candidate at the University of California, Los Angeles - School of Law, where he focused on the intersection of law and medicine. His experience in academia and research has informed his approach to tackling complex medical issues. In addition to his work at Verge Genomics, Huang has been a member of the Board of Directors at California Life Sciences since 2020, further demonstrating his commitment to advancing life sciences in California.
Achievements
Peyton Huang's contributions to the field of genomics and neuroscience are notable. At Verge Genomics, he has been instrumental in raising significant funding and developing a large proprietary patient genomics dataset. His work addresses critical medical challenges, positioning the company as a leader in the genomics space. Huang's academic achievements, including his MD/PhD candidacy and honors from Princeton University, reflect his dedication to advancing medical science.